Immunocore (IMCR) Competitors

Immunocore (NASDAQ:IMCR) and CG Oncology (NASDAQ:CGON) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability.

Is IMCR or CGON more profitable?

CG Oncology has a net margin of 0.00% compared to Immunocore's net margin of -22.48%. CG Oncology's return on equity of 0.00% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunocore	-22.48%	-15.78%	-9.91%
CG Oncology	N/A	N/A	N/A

Which has stronger earnings and valuation, IMCR or CGON?

CG Oncology has lower revenue, but higher earnings than Immunocore.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunocore	$249.43M	11.16	-$55.29M	-$1.16	-48.15
CG Oncology	$200K	11,761.96	-$48.61M	N/A	N/A

Do analysts rate IMCR or CGON?

Immunocore presently has a consensus target price of $80.55, suggesting a potential upside of 44.42%. CG Oncology has a consensus target price of $61.75, suggesting a potential upside of 71.34%. Given CG Oncology's higher probable upside, analysts clearly believe CG Oncology is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
CG Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Do insiders & institutionals have more ownership in IMCR or CGON?

84.5% of Immunocore shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 5.7% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community favor IMCR or CGON?

Immunocore received 37 more outperform votes than CG Oncology when rated by MarketBeat users. However, 71.43% of users gave CG Oncology an outperform vote while only 68.85% of users gave Immunocore an outperform vote.

Company	Underperform	Outperform
Immunocore	Outperform Votes 42 68.85%	Underperform Votes 19 31.15%
CG Oncology	Outperform Votes 5 71.43%	Underperform Votes 2 28.57%

Does the media favor IMCR or CGON?

In the previous week, Immunocore had 1 more articles in the media than CG Oncology. MarketBeat recorded 3 mentions for Immunocore and 2 mentions for CG Oncology. Immunocore's average media sentiment score of 0.76 beat CG Oncology's score of 0.00 indicating that Immunocore is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunocore	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Immunocore beats CG Oncology on 8 of the 15 factors compared between the two stocks.